XML 31 R22.htm IDEA: XBRL DOCUMENT
v3.23.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Revenue related to Novartis agreement: |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 7,696 |  |  | $ | 7,018 |  |  |  |  |
Research services | 2,059 |  |  | 1,877 |  |  |  |  |
Total | $ | 9,755 |  |  | $ | 8,895 |  |  |  |  |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Revenue related to Biogen agreement: |  |  |  |  |  |  |
Recognition of license and other fixed consideration | $ | 130,630 |  |  | $ | 7,306 |  |  |  |  |
Cost-sharing payments for research services, net variable consideration | 1,672 |  |  | 3,887 |  |  |  |  |
Total | $ | 132,302 |  |  | $ | 11,193 |  |  |  |  |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of license fee fixed consideration | $ | 11,440 |  |  | $ | 6,159 |  |  |  |  |
Research services variable consideration | 868 |  |  | 149 |  |  |  |  |
Total | $ | 12,308 |  |  | $ | 6,308 |  |  |  |  |
Sanofi S.A. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | — |  |  | $ | 311 |  |  |  |  |
Research services | — |  |  | 978 |  |  |  |  |
Milestone achievement | — |  |  | 210 |  |  |  |  |
Total | $ | — |  |  | $ | 1,499 |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |